BrandPilot AI has extended its performance marketing technology for a global luxury brand from the US to three European markets: the United Kingdom, Sweden, and France, marking its first deployment in Europe. The US program, live since April 2026, achieved a 73% recovery rate on branded search ad spend, demonstrating significant efficiency improvements. The European expansion operates under the same performance-based model, with compensation tied to advertising efficiencies, though results may vary by market. This move positions BrandPilot to tap into Europe's €131 billion digital ad market and supports potential further growth across regions.
BrandPilot AI expansion to European markets offers context for technology sector trends. For readers following technology stocks, here is Pluang's market snapshot as of Sep 24, 2026 19:51 WIB: out of 150 priced US technology stocks, 21 rose and 126 fell. Notable movers include FSLY at USD 28.32 with a -4.47% change and 99% buy order activity, YOU at USD 40.43 with +3.93% change and 100% buy order activity, and AXTI at USD 70.21 with -3.80% change and balanced buy/sell orders.
Corxel Pharmaceuticals US and Amanat Acquisition Corp have agreed to merge, creating a publicly traded biopharmaceutical company focused on oral obesity treatments. The deal will raise approximately $377 million, including $300 million from private i...
Eikon Therapeutics presented updated data on EIK1001, a TLR7/8 dual-agonist, combined with pembrolizumab and chemotherapy for stage 4 non-small cell lung cancer (NSCLC) at the 2026 ESMO Congress. The treatment showed a 72% objective response rate and...
Microsoft, Alphabet, and Amazon together represent about 15% of the S&P 500 index. All three tech giants are scheduled to report their quarterly earnings within a two-day span. These earnings reports are highly anticipated as they provide insight int...
Conow, in partnership with Tuya Smart, has introduced the Atlas 6000 AC in Germany, a 6 kWh AC-coupled plug-and-play home battery designed to upgrade existing rooftop solar systems. This battery features AI-driven energy management that optimizes hou...
BioNTech and DualityBio announced that their Phase-3 clinical trial DYNASTY-Breast02 met its primary endpoint, demonstrating a statistically significant but moderate improvement in progression-free survival for Trastuzumab Pamirtecan compared to chem...
